Phyto Pharma, Inc. is a phytopharmaceutical and intellectual property holding company which develops innovative cannabis products, using accepted pharmaceutical formulation techniques. The Company uses current Good Manufacturing Practices (cGMP) for its wholly owned brands that include pre-formulation, formulation development, commercial manufacturing, analytical method development and validation and routine quality control analysis.
About Phyto Pharma
Phyto Pharma has the knowledge, expertise, experience and resources to design, formulate, produce and distribute products from conception through shelf readiness. Our ongoing commitment to develop and invest in our proprietary genetics to create products ensures a strong capability and a quality portfolio offering which includes:
Proprietary genetics and formulation for development and delivery systems of nutraceutical products;
Continued focus on research and development and the development of innovative hemp derived consumer products; and
Phyto Pharma will continue to undertake research and development in cannabis genetics/breeding leading to IP product formulation, testing and education.
The Phyto Pharma Closed Loop Process
Genetics
Extraction
Intellectual Property
Formulization
Brands
Phyto Pharma’s proprietary strains of cannabinoids are effective and unlike others within the industry. All of our strains Intellectual Property (IP) are protected through a third party block chain bank. Our extraction and formalization processes are precise ensuring the safety, efficiency and consistency of all the cannabis products we bring to market. Not only have our brands shown proven success, but we’ve also ensured the bioavailability of our products to keep up with increasing consumer demand.
Genetics
Phyto Pharma presently has entered into exclusive relationships for the genetic mapping of proprietary strains within a block chain environment. Our proprietary strains used in our brands are all IP protected within a third party block chain bank, wholly owned by Phyto Pharma IP. Our proprietary genetics have been uniquely selected to produce the most effective cannabinoids for a specific ailment or product, creating truly the first closed loop system from seedling to retail shelves within the industry.
Extraction
Phyto Pharma provides pharmaceutical-grade cannabis products using current Good Manufacturing Practices (cGMP) that include pre-formulation, formulation development, small scale commercial manufacturing, analytical method development and validation, routine quality control analysis, and stability studies. We take special care to address proper extraction methods in order to pull the desired cannabinoids from our starting material, providing the consumer with a true full spectrum extraction.
Intellectual Property
Phyto Pharma’s intellectual property or proprietary formulations and methods can be used for a variety of dosage forms to produce ingredients utilizing pharmaceutical technology for the delivery of cannabis extracts. We have proprietorial extraction methods that deliver a broad and full spectrum extraction that is not currently found elsewhere in the industry. Our objective is to scale and implement a state-based production laboratory model in multiple legal jurisdictions, to test, create and produce pharmaceutical-grade cannabis products through innovative delivery models.
Formulization
Phyto Pharma strives to lead the industry in developing products to improve the human condition and better the lives of those who suffer from disease. It is Phyto Pharma’s intent to position itself to have safe, reliable, proven cannabis products ready for Phase I formulations when such trials become available. Not only do we focus on a true full spectrum extract, we also specialize in creating unique and effective formulas to enhance the bioavailability of our product.
Brands
The Phyto Pharma’s closed loop seed-to-oil and retail products model will disrupt the production of infused products, edibles and beverages. Our unique approach enables producers and cultivators to bring premium, differentiated products, including consumables and topicals to market safely and efficiently. We manufacture, market and sell consumer products containing plant-based CBD under our Phyto Pharma brands including Phytocine™ and Rehab Rx™ in a range of market sectors including nutraceutical, beauty care and specialty edibles. Currently, manufacturing and distributing more than seven (7) stock-keeping units (SKU’s) and expecting to develop and launch new brands increasing Phyto Pharma’s portfolio of CBD and hemp-related consumer products.
